Become Affiliate

PepFlow

Download

The NAD Precursor

NMN

NMN, or nicotinamide mononucleotide, is an oral NAD+ precursor studied in randomized human trials for NAD-related biomarkers and selected metabolic or physical-function outcomes.

NAD+ aging biologyMetabolic health
TierB
EvidenceModerate
SafetyModerate Data
FDA statusNot Approved
Last reviewed October 25, 2026 35 citations How to read these labels

What is NMN?

NMN is nicotinamide mononucleotide, a biosynthetic precursor used by cells to make NAD+.[1][2][5]

The default oral protocol uses the lowest NMN dose from a randomized 60-day dose-ranging trial and does not borrow an NR or direct NAD+ presentation.[1][2][5]

What NMN is investigated for

NMN evidence is grouped by practical use case and oral, sublingual, intravenous, topical, and transdermal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

NAD+ biomarker support

Oral

70%Moderate

Oral NAD+ biomarker restoration is the most reproducible NMN finding; it is not proof of symptom, disease, or longevity benefit.[7][8][13]

Human evidence

Randomized human studies and meta-analysis show that oral NMN increases blood NAD+ and related metabolites across several short exposure windows.[1][2][5][7][12]

Animal / mechanistic evidence

The biological rationale is supported by established NAD biosynthesis, while this confidence score is anchored to human oral biomarker studies.[1][2][5]

Glucose and metabolic health

Oral

55%Emerging

NMN is not established as a treatment for insulin resistance, diabetes, dyslipidemia, or weight loss.[7][8]

Human evidence

One randomized study in postmenopausal women with prediabetes improved muscle insulin sensitivity, but pooled randomized evidence found no consistent glucose or lipid benefit across adults.[15][7][8]

Animal / mechanistic evidence

Metabolic benefits are biologically plausible and prominent in model systems, but human results are population- and endpoint-dependent.[6][26]

Physical function and exercise performance

Oral

55%Emerging

Physical-performance effects remain limited and should not be promised for healthy users or generalized across populations.[9][10]

Human evidence

Small trials report selected aerobic-capacity, walking-speed, fatigue, or physical-performance signals, while systematic reviews find inconsistent effects across measures.[16][4][20][9][10]

Animal / mechanistic evidence

Mitochondrial and muscle rationale is stronger in preclinical models than the pooled human functional evidence.[6][26]

Vascular health

Oral

52%Emerging

NMN is not an established antihypertensive or vascular treatment.[18][11]

Human evidence

Small trials and a blood-pressure meta-analysis report heterogeneous vascular findings, with insufficient evidence for a reliable treatment effect.[18][11]

Animal / mechanistic evidence

Vascular NAD+ biology provides rationale but does not establish human blood-pressure or arterial-stiffness benefit.[6][26]

Sleep and fatigue

Oral

45%Preliminary

Sleep and fatigue benefits remain emerging and should be reassessed rather than assumed.[4][20]

Human evidence

Small older-adult trials report selected sleep-quality or fatigue signals, but endpoints, populations, and findings are not yet consistent enough for a dependable effect.[4][19][20]

Animal / mechanistic evidence

Circadian and energy-metabolism rationale is indirect and does not determine an expected clinical response.[6][26]

Healthy aging and longevity

Oral

16%Insufficient

NMN should be described as a studied NAD+ precursor, not a proven anti-aging or lifespan-extending treatment.[26][13]

Human evidence

Human trials demonstrate NAD+ biomarker engagement but not lifespan extension or broad prevention of age-related disease.[26][13]

Animal / mechanistic evidence

Aging-pathway and animal evidence motivates human study but cannot establish a human longevity effect.[6][26]

Evidence snapshot

70%

Human evidence

Moderate

Human trials include daily 250 mg and dose-ranging 300, 600, and 900 mg regimens.[1][2][5]

30%

Animal / preclinical

Limited

Preclinical biology is extensive, but it does not replace the route-matched human oral evidence.[1][2][5]

72%

Mechanism support

Moderate

NMN is a direct biosynthetic precursor to NAD+.[1][2][5]

Forms & administration

NMN has oral capsule and tablet presentations, alongside investigational sublingual and intravenous formulations. Experimental wound gels and assisted skin-delivery systems have mainly laboratory or animal evidence. Each form needs its own preparation and amount; an ongoing intravenous course is not established.[1][25][3][30][31][32]

OralSublingualIntravenousTopicalTransdermal

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common oral protocols use 300 mg per day.[1]

Frequency

Usually taken once daily.[1]

Timing Considerations

Morning is the usual timing.[1]

Cycle Length

Common oral cycles run 60 days.[1]

What to expect

First 1–2 weeks

Blood NAD+ and related metabolites can rise within early study windows, but a biomarker response does not predict a noticeable clinical effect.[14][2][12]

Weeks 4–8

Many trials reassess NAD+ biomarkers, tolerability, and exploratory metabolic or physical outcomes in this range; lack of a symptom change is compatible with the evidence.[1][7][8]

Weeks 8–12

Sleep, fatigue, walking, and vascular outcomes in longer small trials are mixed and population-specific; they are not guaranteed milestones.[4][18][20]

After stopping

The durability of biomarker or symptom changes after stopping is not consistently mapped; NMN should not be assumed to create a permanent NAD+ increase.[6][13]

Safety profile

Short oral trials and recent pooled analyses generally report acceptable tolerability without a consistent excess serious-adverse-event pattern, but multi-year use, special populations, and product-to-product quality remain incompletely characterized.[1][2][17][12]

Cautions

What we don't know

Multi-year use, pregnancy, pediatric use, cancer-specific risk, and equivalence across formulations remain insufficiently studied.[26][13][12]

Who NMN is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding without clinician review

    Pregnancy and breastfeeding safety data are insufficient for the reviewed oral use.[26][13]

How it works

NMN sits immediately upstream of NAD+ in the salvage pathway, which is why oral studies measure circulating NAD-related metabolites after supplementation.[1][2][5]

Oral exposure and metabolism differ from direct NAD+ administration and from nicotinamide riboside, so the molecule keeps its own dose and route record.[1][2][5]

Research gaps & open questions

What the current literature has not yet settled about NMN:

01

Longer controlled trials need to test clinical outcomes rather than only NAD-related biomarkers.[1][2][5]

02

Independent trials should compare multiple NMN amounts and better define safety in older adults and people with chronic conditions.[1][2][5]

03

Metabolic studies need to resolve why the muscle insulin-sensitivity signal in one population has not translated into consistent pooled glucose or lipid outcomes.[15][7][8]

04

Physical-function and sleep signals need replication with clearly chosen outcomes, clinically meaningful effect thresholds, and diverse populations.[9][10][20]

05

Multi-year safety, post-discontinuation durability, and outcomes in pregnancy, cancer, and polypharmacy remain insufficiently studied.[26][13][12]

Common questions

Is NMN direct NAD+?

No. NMN is a precursor used in NAD+ biosynthesis; direct NAD+ is a different canonical entry.[1][2][5]

Does NMN have proven anti-aging or longevity benefits?

No human trial has shown lifespan extension. NMN raises NAD-related biomarkers, but downstream clinical outcomes are mixed and generally short-term.[26][13]

Does NMN improve blood sugar or insulin resistance?

Not reliably across adults. One targeted trial improved muscle insulin sensitivity, while meta-analyses found no consistent glucose or lipid benefit.[15][7][8]

Does NMN reliably improve exercise or physical performance?

Small trials report selected signals, but pooled evidence is mixed and does not support a guaranteed performance effect.[16][9][10]

Is NMN banned as a dietary supplement in the United States?

FDA's September 2025 response concluded that NMN is not excluded from the dietary-supplement definition. That does not make NMN an FDA-approved drug or approve every product.[28]

Myths & misconceptions

Myth

NMN and NR are interchangeable names.

Reality

They are distinct NAD+ precursors with separate trial and product records.[1][2][5]

Myth

A higher blood NAD+ result proves that NMN is improving health.

Reality

Blood NAD+ is a target-engagement biomarker. Meta-analyses show that it can rise even when glucose, lipid, muscle, or other clinical outcomes do not improve.[7][8][10]

Myth

Dietary-supplement status means NMN is FDA-approved.

Reality

No. Eligibility under the dietary-supplement definition and FDA approval of a drug are different regulatory pathways.[28][33]

History & discovery

NMN is a nucleotide intermediate in NAD+ biosynthesis rather than a peptide. Human research began with short oral safety and metabolism studies, then expanded into randomized trials of NAD+ biomarkers, insulin sensitivity, physical function, vascular measures, sleep, and disease-specific questions. Biomarker engagement is more consistent than downstream clinical benefit.[6][14][26][13]

A small study in healthy men described short-term oral safety and nicotinamide-metabolite handling.[14]

Trials evaluated insulin sensitivity, aerobic capacity, sleep, physical performance, blood NAD+, and arterial stiffness.[15][16][4][18]

Meta-analyses found reliable NAD+ biomarker engagement but heterogeneous or mostly null cardiometabolic outcomes, while new disease-specific trials remained early.[7][8][23][12]

Published research35 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Build consistency around your healthy-aging goals.

Use PepFlow to record your NMN protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00